Page 27 - Gerhemder bülten 3

polifarmasiyi önlemek için kesin tanı konulmadan tedaviye başlanılmamalı, aynı hastalık için başka hekimler
tarafından ilaç reçetesi yazılıp yazılmadığı kontrol edilerek mümkün olan en az sayıda ve en düşük dozda te-
daviye başlanmalı, doz arttırımı gerekiyorsa kontrollü ve düşük dozlarda yapılmalı, hastalara kullanım şeması
hazırlanmalı ve ilaç kutuları hastanın anlayabileceği şekilde işaretlenmeli, uzun süreli kullanılması zorunlu
olmayan ilaçlar mümkün olduğunca kısa süreli kullanılmalı ve kesilmeli, tedavi düzenli olarak gözden geçiri-
lerek tekrarlı yazımlar önlenerek gereksiz ve/veya endikasyonu biten ilaçlar tedaviden çıkarılmalıdır.

Kaynaklar

1) Marcel E. Salive, Multimorbidity in Older Adults, Epidemiologic Reviews, Volume 35, Issue 1, 2013,
Pages 75–83
2) Andrew Kingston, Louise Robinson, Heather Booth, Martin Knapp, Carol Jagger, for the MODEM
project, Projections of multi-morbidity in the older population in England to 2035: estimates from the Popu-
lation Ageing and Care Simulation (PACSim) model, Age and Ageing, Volume 47, Issue 3, May 2018, Pages
374–380
3) Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of
definitions. BMC Geriatr. 2017 Oct 10;17(1):230.
4) World Health Organization (2019) Medication Safety in Polypharmacy (WHO/UHC/SDS/2019.11).
https://apps.who.int/iris/bitstream/handle/10665/325454/WHO-UHC-SDS-2019.11-eng.pdf?ua=1. (29 Şubat
2023 tarihinde erişilmiştir)
5) Guillot J, Maumus-Robert S, Bezin J (2020) Polypharmacy: a general review of definitions, descriptions
and determinants. Therapies 75(5):407–416
6) Khezrian M et al (2020) An overview of prevalence, determi nants and health outcomes of polyphar-
macy. Ther Adv Drug Saf 11:1–10
7) Midao L et al (2018) Polypharmacy prevalence among older adults based on the survey of health, age-
ing and retirement in Europe. Arch Gerontol Geriatr 78:213–220
8) O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, Gudmundsson A,
Cruz-Jentoft AJ, Knol W, Bahat G, van der Velde N, Petrovic M, Curtin D. STOPP/START criteria for potenti-
ally inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023 Aug;14(4):625-632.
9) American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medicati-
on use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081.
10) Mann NK, Mathes T, Sönnichsen A, Pieper D, Klager E, Moussa M, Thürmann PA. Potentially Ina-
dequate Medications in the Elderly: PRISCUS 2.0. Dtsch Arztebl Int. 2023 Jan 9;120(1-2):3-10.
11) Kuhn-Thiel AM, Weiß C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a cli-
nical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs & aging. 2014;31(2):131-
40.
12) Bahat, G., Ilhan, B., Erdogan, T. et al. Turkish inappropriate medication use in the elderly (TIME) cri-
teria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START. Eur Geriatr Med 11, 491–498
(2020).
13) Palmer K et al (2019) Association of polypharmacy and hyper polypharmacy with frailty states: a sys-
tematic review and meta analysis. Eur Geriatr Med 10(1):9–36
14) Pazan, F., & Wehling, M. (2021). Polypharmacy in older adults: a narrative review of definitions, epide-
miology and consequences. European geriatric medicine, 12, 443-452.

27